Overview
This randomized, single-blind, crossover study compares remimazolam and propofol for monitored anesthetic care during fractional ablative CO₂ laser therapy for burn scars. The primary aim is to assess incidence of respiratory depression, defined as a need for advanced airway maneuvers (jaw thrust/chin lift, insertion of oral or nasal airway, or bag mask ventilation), and hypopnea (respiratory rate \< 8).
Description
Patients will be randomized to receive either remimazolam or propofol during their first laser session, and the alternate drug during their second session 4-6 weeks later. Outcomes include respiratory depression, sedation onset and recovery times, hemodynamic changes, and patient satisfaction.
Eligibility
Inclusion Criteria:
- Age ≥ 18 years
- Undergoing both outpatient Session #1 and Session #2 of fractional ablative CO2 laser therapy
Exclusion Criteria:
- History of previous fractional ablative laser therapy for burn scar
- Procedure expected to last longer than 30 minutes
- Allergy such as dextran 40 or contraindication to either of the study drugs
- Pregnant and/or breastfeeding
- Subjects who are unable to or choose not to give informed consent